Many exogenous peroxisome proliferators (PP) are agonists of PPAR, as evidenced by the fact that PPARγ and PPARα are respective molecular targets for the type 2 diabetes drug thiazolidinediones (TZDs) and for dyslipidemia drug fibrates. Here, PPARA is linked to metabolic syndrome.